(Q44356292)

2 December 2017

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures (English)

1 reference

cost-effectiveness analysis

2 December 2017

1 reference

1

Olof Johnell

1 reference

2 December 2017

Bengt Jönsson

2

1 reference

2 December 2017

Linus Jönsson

series ordinal

3

1 reference

2 December 2017

Dennis Black

series ordinal

4

1 reference

2 December 2017

language of work or name

1 reference

1 January 2003

1 reference

2 December 2017

1 reference

2 December 2017

21

1 reference

2 December 2017

5

1 reference

2 December 2017

305-314

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200321050-00002

2 December 2017

0 references

cites work

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

1 reference

12 December 2020

The cost of a hip fracture. Estimates for 1,709 patients in Sweden

1 reference

12 December 2020

The economics of osteoporosis and its prevention. A review

1 reference

12 December 2020

1 reference

12 December 2020

The diagnosis of osteoporosis

1 reference

12 December 2020

Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials.

1 reference

12 December 2020

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors.

1 reference

12 December 2020

Targeting high-risk populations.

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

12 December 2020

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

1 reference

12 December 2020

Cost-effectiveness of fracture prevention in established osteoporosis.

1 reference

12 December 2020

A computer model to analyze the cost-effectiveness of hormone replacement therapy

1 reference

12 December 2020

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation

1 reference

12 December 2020

Estrogen use in postmenopausal women--costs, risks, and benefits

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Long-term risk of osteoporotic fracture in Malmö.

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered

1 reference

12 December 2020

10.2165/00019053-200321050-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

2 December 2017

0 references

1 reference